E
Emilio Bria
Researcher at Catholic University of the Sacred Heart
Publications - 396
Citations - 9272
Emilio Bria is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 40, co-authored 325 publications receiving 6857 citations. Previous affiliations of Emilio Bria include Agostino Gemelli University Polyclinic & University of Verona.
Papers
More filters
Journal ArticleDOI
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
Fausto Roila,Jørn Herrstedt,Matti Aapro,Richard J. Gralla,Lawrence H. Einhorn,Enzo Ballatori,Emilio Bria,R. A. Clark-Snow,Birgitte T. Espersen,P. Feyer,Steven M. Grunberg,Paul J. Hesketh,Karin Jordan,Mark G. Kris,Ernesto Maranzano,Alex Molassiotis,Garry R. Morrow,Ian N. Olver,Bernardo Leon Rapoport,Cynthia N. Rittenberg,Mitsue Saito,Maurizio Tonato,David Warr +22 more
TL;DR: This guideline process was based on a literature review through 1 June 2009 using MEDLINE and other databases and believes that this is the most representative and evidence-based guideline process that has yet been performed.
Journal ArticleDOI
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Sylvestre Le Moulec,L. Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Serge Koscielny,Stéphane Champiat,Charles Ferté,David Planchard,Jordi Remon,Marie Eve Boucher,Anas Gazzah,Julien Adam,Emilio Bria,Giampaolo Tortora,Jean-Charles Soria,Benjamin Besse,Benjamin Besse,Caroline Caramella +28 more
TL;DR: It is suggested that HPD is more common with PD-1/PD-L1 inhibitors compared with chemotherapy in pretreated patients with NSCLC and is also associated with high metastatic burden and poor prognosis in patients treated with PD.
Journal ArticleDOI
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Marina Chiara Garassino,Jennifer G. Whisenant,Li-Ching Huang,Annalisa Trama,Valter Torri,Francesco Agustoni,Javier Baena,Giuseppe Luigi Banna,Rossana Berardi,Anna Cecilia Bettini,Emilio Bria,Matteo Brighenti,Jacques Cadranel,Alessandro De Toma,Claudio Chini,Alessio Cortellini,Enriqueta Felip,Giovanna Finocchiaro,Pilar Garrido,Carlo Genova,Raffaele Giusti,Vanesa Gregorc,Francesco Grossi,Federica Grosso,Salvatore Intagliata,Nicla La Verde,Stephen V. Liu,Julien Mazieres,Edoardo Mercadante,Olivier Michielin,Gabriele Minuti,Denis Moro-Sibilot,Giulia Pasello,Antonio Passaro,Vieri Scotti,Piergiorgio Solli,Elisa Stroppa,Marcello Tiseo,Giuseppe Viscardi,Luca Voltolini,Yi-Long Wu,Silvia Zai,Vera Pancaldi,Anne Marie C. Dingemans,Jan P. van Meerbeeck,Fabrice Barlesi,Heather A. Wakelee,Solange Peters,Leora Horn +48 more
TL;DR: With an ongoing global pandemic of COVID-19, the data suggest high mortality and low admission to intensive care in patients with thoracic cancer and whether mortality could be reduced with treatment in intensive care remains to be determined.
Journal ArticleDOI
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Luisa Carbognin,Sara Pilotto,Michele Milella,Vanja Vaccaro,Matteo Brunelli,Anna Caliò,Federica Cuppone,Isabella Sperduti,Diana Giannarelli,Marco Chilosi,Vincenzo Bronte,Aldo Scarpa,Emilio Bria,Giampaolo Tortora +13 more
TL;DR: Overall, the three antibodies provide a significant differential effect in terms of activity according to PD-L1 expression on tumor cells, which seems to be more robust for anti-PD-1 antibody (nivolumab and pembrolizumab), and in the context of advanced melanoma and NSCLC.
Journal ArticleDOI
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials
Emilio Bria,Federica Cuppone,Monica Fornier,Cecilia Nisticò,Paolo Carlini,Michele Milella,Isabella Sperduti,Edmondo Terzoli,Francesco Cognetti,Diana Giannarelli +9 more
TL;DR: The overall outcome results show that trastuzumab is one of the most important discoveries in oncology and needs to be investigated more extensively to explore both long-term safety and specific relapse patterns.